Taliglucerase alfa
- Generic Name
- Taliglucerase alfa
- Brand Names
- Elelyso
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 37228-64-1
- Unique Ingredient Identifier
- N69L6LM4QU
- Background
Taliglucerase alfa is the recombinant active form of the human lysosomal enzyme, β-glucocerebrosidase. It was approved in 2012 and is marketed under the name Elelyso for use in patients with type 1 Gaucher's disease.
- Indication
For the treatment of adult Type 1 Gaucher disease.
- Associated Conditions
- Gaucher Disease, Type 1, Gaucher Disease, Type III
- Associated Therapies
- -
Assessing the Impact of Elelyso on Bone Involvement Currently Treated With Other ERTs
- Conditions
- Interventions
- First Posted Date
- 2020-04-20
- Last Posted Date
- 2022-10-28
- Lead Sponsor
- Shaare Zedek Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT04353466
A Multicenter, Safety and Efficacy Study of Taliglucerase Alfa in Subjects With Type 3 Gaucher Disease
- First Posted Date
- 2019-07-01
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Ari Zimran
- Target Recruit Count
- 14
- Registration Number
- NCT04002830
- Locations
- 🇮🇱
Shaare Zedek Medical Center, Jerusalem, Israel
🇮🇳All India Institute of Medical Sciences, New Delhi, India
🇹🇷Gazi University, Ankara, Turkey
A Multicenter Extension Study of Taliglucerase Alfa in Adult Subjects With Gaucher Disease
- First Posted Date
- 2011-08-23
- Last Posted Date
- 2023-04-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 19
- Registration Number
- NCT01422187
A Multicenter Extension Study of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease
- First Posted Date
- 2011-08-08
- Last Posted Date
- 2018-09-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 15
- Registration Number
- NCT01411228
- Locations
- 🇮🇱
Shaare Zedek Medical Center, Jerusalem, Israel
🇿🇦Morningside Medi-Clinic, Morningside, South Africa
🇵🇾Instituto Privado de Hematologia E Investigacion Clinica (I.P.H.I.C), Barrio Asuncion, Paraguay
A Safety and Efficacy Study of Two Dose Levels of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease
- First Posted Date
- 2010-05-28
- Last Posted Date
- 2018-10-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 11
- Registration Number
- NCT01132690
- Locations
- 🇵🇾
Instituto Privado de Hematologia E Investigacion Clinica (I.P.H.I.C), Barrio Sajonia Asunción, Paraguay
🇮🇱Shaare Zedek Medical Center, Jerusalem, Israel
🇿🇦Morningside Medi-Clinic, Morningside, South Africa
Switchover Trial From Imiglucerase to Plant Cell Expressed Recombinant Human Glucocerebrosidase
- First Posted Date
- 2008-07-10
- Last Posted Date
- 2018-10-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 31
- Registration Number
- NCT00712348
- Locations
- 🇮🇱
Shaare Zedek Medical Center, Jerusalem, Israel
🇬🇧Royal Free Hospital, London, United Kingdom
🇬🇧Lysosomal Disorders Service, Addenbrookes Hospital NHS Trust, Cambridge, United Kingdom
Plant Cell Expressed Recombinant Human Glucocerebrosidase Extension Trial
- First Posted Date
- 2008-06-27
- Last Posted Date
- 2018-10-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 45
- Registration Number
- NCT00705939
- Locations
- 🇨🇱
Pontificia Universidad Catolica de Chile, Santiago, Chile
🇦🇺Bone Marrow Transplant Service, The Royal Melbourne Hospital, Parkville, Victoria, Australia
🇺🇸Department of Human Genetics, Emory University School of Medicine, Decatur, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.